Literature DB >> 22858080

The impact of heart failure on the classification of COPD severity.

Gülmisal Güder1, Frans H Rutten, Susanne Brenner, Christiane E Angermann, Dominik Berliner, Georg Ertl, Berthold Jany, Jan-Willem J Lammers, Arno W Hoes, Stefan Störk.   

Abstract

BACKGROUND: Pulmonary restriction-a reduction of lung volumes-is common in heart failure (HF), rendering severity grading of chronic obstructive pulmonary disease (COPD) potentially problematic in subjects with both diseases. We compared pulmonary function in patients with either HF or COPD, or the combination to assess whether grading of COPD using the Global Initiative of Chronic Obstructive Lung Disease classification is hampered in the presence of HF. METHODS AND
RESULTS: In 2 cohorts involving 591 patients with established HF and 405 with a primary care diagnosis of COPD, the presence of HF and COPD was assessed according to guidelines. HF severity was staged according to the NYHA classification system into Classes I-IV. COPD was diagnosed if the ratio of post-bronchodilator forced expiratory volume in 1 second and forced vital capacity (FEV1/FVC) was <0.70, and categorized in GOLD stages I-IV according to post-bronchodilator-predicted FEV1 levels (FEV1% ≥80%; 50-79%; 30-49%; <30%). In total, 557 patients with HF only, 108 with HF+COPD, and 194 with COPD only were studied. Patients, who had neither HF nor COPD according to definition, or HF with reversible obstruction in post-bronchodilator pulmonary function tests were excluded from this analysis (n = 137). Compared with COPD only, patients with HF plus COPD had higher levels of post-bronchodilator FEV1/FVC (median [quartiles] 0.57 [0.47-0.64] vs 0.62 [0.55-0.66] and lower total lung capacity % (115 [104-126]% vs 105 [95-117]%, P < .001) P < .001), but comparable levels of post-bronchodilator FEV1% (70 [56-84]% vs 68 [54-80]%, P = .22) and thus similar distributions of GOLD stages I-IV in both groups (24/56/19/4% vs 31/50/19/1%, P = .57). In patients with HF only, 25% exhibited pre-bronchodilator FEV1% levels of <80% (FEV1% 94 [80-108]%), despite a pre-bronchodilator FEV/FVC ratio ≥0.7 in this group. The reduction of FEV1 in patients with HF only was associated with HF severity.
CONCLUSIONS: In stable HF, FEV1 may be significantly reduced even in the absence of "real" airflow obstruction. In this situation, diagnosing COPD according to GOLD criteria (based on FEV1/FVC) still seems feasible, because both FEV1 and FVC are usually decreased to an equal extent in HF. However, classifying COPD based on FEV1 levels may overrate obstruction severity in patients with combined disease (HF plus COPD), and thus may lead to unjustified use of bronchodilators.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22858080     DOI: 10.1016/j.cardfail.2012.05.008

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  13 in total

Review 1.  Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence.

Authors:  Gülmisal Güder; Frans H Rutten
Journal:  Curr Heart Fail Rep       Date:  2014-09

2.  What the General Practitioner Needs to Know About Their Chronic Heart Failure Patient.

Authors:  Frans H Rutten; Joe Gallagher
Journal:  Card Fail Rev       Date:  2016-11

Review 3.  Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.

Authors:  Abhishek Jaiswal; Astha Chichra; Vinh Q Nguyen; Taraka V Gadiraju; Thierry H Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2016-02

Review 4.  Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?

Authors:  Sergio Caravita; Jean-Luc Vachiéry
Journal:  Curr Heart Fail Rep       Date:  2016-12

5.  Right Ventricular and Pulmonary Computed Tomography Assessments in Paradoxical Low-Flow Low-Gradient Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Marzia Rigolli; Ryan Reeves; Christopher Smitson; Jenny Yang; Mona Alotaibi; Ehtisham Mahmud; Atul Malhotra; Francisco Contijoch
Journal:  Struct Heart       Date:  2022-03-30

6.  Impact of reduced forced expiratory volume on cardiac prognosis in patients with chronic heart failure.

Authors:  Yuki Honda; Tetsu Watanabe; Yoichiro Otaki; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Tetsuro Shishido; Takuya Miyamoto; Yoko Shibata; Isao Kubota
Journal:  Heart Vessels       Date:  2018-03-19       Impact factor: 2.037

7.  COPD in patients with stable heart failure in the primary care setting.

Authors:  Mark J Valk; Berna D Broekhuizen; Arend Mosterd; Nicolaas P Zuithoff; Arno W Hoes; Frans H Rutten
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-26

Review 8.  Epidemiology and clinical impact of major comorbidities in patients with COPD.

Authors:  Miranda Caroline Smith; Jeremy P Wrobel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-08-27

9.  Prevalence of airflow obstruction in patients with stable systolic heart failure.

Authors:  Morten Dalsgaard; Louis Lind Plesner; Morten Schou; Erik Kjøller; Jørgen Vestbo; Kasper Iversen
Journal:  BMC Pulm Med       Date:  2017-01-06       Impact factor: 3.317

10.  Diagnostic and prognostic utility of mid-expiratory flow rate in older community-dwelling persons with respiratory symptoms, but without chronic obstructive pulmonary disease.

Authors:  Gülmisal Güder; Susanne Brenner; Stefan Störk; Matthias Held; Berna D L Broekhuizen; Jan-Willem J Lammers; Arno W Hoes; Frans H Rutten
Journal:  BMC Pulm Med       Date:  2015-07-31       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.